Overview

Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)

Status:
Recruiting

Trial end date:
2022-12-15

Target enrollment:

Participant gender:

Summary

This is a multicenter, open-label, non-comparator, single-arm study to evaluate the efficacy, safety, tolerability and PK (pharmacokinetics) of oral SCY-078 as an emergency use treatment for patients with a documented Candida auris infection.

Phase:

Phase 3

Details

Lead Sponsor:

Scynexis, Inc.

Treatments:

Ibrexafungerp